tiprankstipranks
Trending News
More News >
SCOR SE (SCRYY)
OTHER OTC:SCRYY

SCOR SE (SCRYY) AI Stock Analysis

Compare
15 Followers

Top Page

SCRYY

SCOR SE

(OTC:SCRYY)

Select Model
Select Model
Select Model
Neutral 67 (OpenAI - 5.2)
Rating:67Neutral
Price Target:
$4.00
▲(21.21% Upside)
Action:ReiteratedDate:03/19/26
The score is driven primarily by solid (but not consistently compounding) financial performance—strong cash generation and reasonable leverage offset by revenue erosion and earnings volatility. Technicals are supportive with price above key moving averages and positive momentum signals. The earnings call adds a meaningful positive boost due to strong profitability, solvency, and confident guidance, while valuation remains the main drag due to the very high P/E despite an attractive dividend yield.
Positive Factors
Capital adequacy & high ROE
SCOR's 215% Solvency II ratio and 19.1% ROE reflect a durable capital buffer and strong return generation. That level of solvency supports sustained underwriting capacity, dividend policy and opportunistic buffer building, and provides resilience to absorb larger losses over the coming months.
Consistent cash generation
Consistently positive operating and free cash flows provide SCOR with reliable internal funding for claims, investments and shareholder returns. This steady cash generation increases financial flexibility, reduces reliance on external funding and supports durable capital management over a 2–6 month horizon.
Underwriting discipline and cost savings
Outperforming P&C combined ratio targets and €170m of cost savings (ahead of plan) point to sustainable underwriting discipline and structural expense control. Together they improve margin durability, allow competitive but disciplined pricing, and underpin medium‑term profitability and dividend support.
Negative Factors
Declining revenue trend
A multi-year top‑line decline reduces SCOR's underwriting scale and the insurance 'float' that funds investment income. Sustained revenue erosion can constrain growth, weaken pricing leverage with cedants, and limit long-term investment return potential, making capital allocation and growth harder to execute.
Earnings and margin volatility
Material swings in profitability and margins reflect exposure to nat‑cat, man‑made events and cyclical pricing. Persistent volatility complicates capital planning, weakens forward earnings visibility and increases the risk that dividends, buybacks or reinvestment plans must be adjusted when adverse claims experience re-emerges.
Regulatory reform and refinancing timing risk
Pending Solvency II reform (estimated -10–15ppt impact) and a near‑term Tier‑2 call/refinancing create structural capital and funding uncertainty. If reforms reduce available capital or refinancing costs rise, SCOR may need to raise capital, cut distributions, or adjust underwriting strategy—affecting medium‑term positioning.

SCOR SE (SCRYY) vs. SPDR S&P 500 ETF (SPY)

SCOR SE Business Overview & Revenue Model

Company DescriptionSCOR SE, together with its subsidiaries, provides life and non-life reinsurance products in Europe, the Middle East, Africa, the Americas, Latin America, and Asia Pacific. It operates through two segments, SCOR Global P&C and SCOR Global Life. The SCOR Global P&C segment offers reinsurance products in the areas of property, motors, casualty treaties, credit and surety, decennial insurance, aviation, marine and energy, engineering, agricultural risks, and property catastrophes; specialties insurance products, including business solutions, political and credit risks, cyber, and environmental impairment liability; and business ventures and partnerships. The SCOR Global Life segment provides life reinsurance products, including protection for mortality, morbidity, behavioral risks, disability, long-term care, critical illness, medical, and personal accident. This segment also provides financial solutions that combine traditional life reinsurance with financial components and provide liquidity, balance sheet, solvency, and income improvements to clients; longevity solutions that include products covering the risk of negative deviation from expected results due to the insured or annuitant living longer than assumed in the pricing of insurance covers provided by insurers or pension funds; and distribution solutions. In addition, it is involved in the asset management business. The company was founded in 1970 and is headquartered in Paris, France.
How the Company Makes MoneySCOR makes money primarily by underwriting reinsurance and investing the capital ("float") generated from its insurance operations. 1) Reinsurance underwriting revenue (core business) - Property & Casualty (P&C) reinsurance: SCOR assumes a portion of insurers’ risks for lines such as catastrophe, property, and casualty exposures. SCOR earns reinsurance premiums from cedants (primary insurers) in exchange for agreeing to cover specified losses under treaty or facultative reinsurance contracts. Profitability depends on pricing/terms, claims experience (including catastrophe events), and expense discipline; underwriting income is generated when earned premiums exceed claims and operating costs. - Life & Health (L&H) reinsurance: SCOR reinsures biometric risks (e.g., mortality, longevity, disability, critical illness) and in some cases financial risks embedded in life/health products. It earns premiums and/or fee-like margins (depending on contract structure) while paying claims and benefits when covered events occur. Results depend on experience (e.g., mortality and morbidity trends), lapse behavior, and contract design. 2) Investment income (supporting earnings) - SCOR invests the assets backing its technical reserves and shareholders’ equity in a diversified investment portfolio. It earns income from interest, coupons, dividends, and realized/unrealized gains or losses. Investment returns are an important driver of overall earnings because reinsurance premiums are collected before many claims are paid, allowing SCOR to invest those funds over time. 3) Fees and other income (if applicable) - To the extent SCOR provides additional services associated with reinsurance relationships (e.g., risk analytics, structuring, or related support embedded in reinsurance arrangements), economics are typically reflected in the pricing/margins of reinsurance contracts rather than as separately disclosed standalone service revenue. If a specific, separately reported fee line is not available, null.

SCOR SE Earnings Call Summary

Earnings Call Date:Mar 04, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call was predominantly positive: SCOR reported record net income, robust ROE, strong solvency (215%), significant economic value growth (+13.7% vs 9% target), a raised dividend (+5.6%), EUR 170m of cost savings ahead of plan, excellent P&C underwriting metrics (combined ratio well below target, nat cat and attritional loss ratios improving), and Life & Health and investment results beating guidance. Key risks and headwinds were noted but appear manageable: competitive P&C pricing and SBS weakness, some underperforming Life contracts (addressed with reserve strengthening), refinancing timing on Tier 2, man-made loss volatility, pending arbitration, and potential Solvency II reform impacts (estimated -10–15ppt). Overall, the positive operational and capital outcomes materially outweigh the identified lowlights.
Q4-2025 Updates
Positive Updates
Record Full-Year Net Income
Net income for FY2025 was EUR 846 million, the highest in SCOR's history, supported by strong contributions from P&C, Life & Health and Investments.
Strong Return on Equity
Return on equity reached 19.1% for the full year; Q4 implied annualized ROE was 21.1%, both well above group targets.
Robust Solvency Position
Group Solvency II ratio of 215%, up 5 percentage points versus 2024 and at the higher end of the target range, reflecting satisfactory net operating capital generation in 2025.
Economic Value Growth
Economic value grew 13.7% at constant economics for the year, outperforming the Forward '26 target of 9% per annum; economic value per share stands at EUR 48, broadly stable year-over-year.
Dividend Increase and Capital Management
Executive Committee proposed a dividend of EUR 1.9 per share for FY2025, up 5.6% from EUR 1.8, which will set the new dividend floor under the ratchet policy.
Cost Savings and Expense Discipline
Achieved EUR 170 million of savings after 2 years—one year ahead of plan—allowing management expenses to remain flat versus 2023; group expense ratio for 2025 around 7.4% with long-term guidance of 7–8%.
P&C Underwriting Strength
P&C combined ratio continues to outperform Forward '26 target (below 87%); Q4 nat cat ratio 7.6% (YTD 6.8%), well within the annual budget of 10%; Q4 attritional loss ratio 74.7% (YTD 76.4%), improved from 77% in 2024.
Life & Health Outperformance
Life & Health full-year new business CSM of EUR 464 million (above EUR 0.4bn assumption); Q4 new business CSM EUR 170 million; insurance service result EUR 115 million in Q4 and EUR 450 million for the year, ahead of the ~EUR 0.4bn guidance.
Investment Returns and Yield
Return on invested assets was 3.6% in Q4 generating EUR 209 million of investment income; regular income yield ~3.8%; credit portfolio remains high quality with expected credit losses broadly unchanged.
Balance Sheet and Risk Management Enhancements
Financial leverage managed proactively (25.3% vs 24.5% prior), successful issuance of Tier 2; increased group risk-adjustment confidence level to 75.5%–82.5%; ongoing improvements in ALM (moving toward dynamic ALM) and tech/data (6 AI flagship projects in progress).
Negative Updates
P&C Revenue Pressure and SBS Weakness
P&C insurance revenue down 1.6% in Q4 at constant FX; on a full-year basis, adjusted insurance revenue was flat with reinsurance up 2% but SBS down 4%, reflecting softness in some segments.
Competitive Pricing and Margin Pressure
More competitive P&C pricing environment and margin pressure in certain inward and specialty lines were noted; January renewals were managed with disciplined underwriting but highlighted market softness.
Life & Health Loss Component and Onerous Contracts
A negative loss component emerged related to a limited number of underperforming contracts (notably an Israeli runoff portfolio), with cumulative adjustments through the year (examples cited: Q1 -€6m, Q2 -€10m, Q3 -€20m and further year-end adjustments) leading to prudential reserve actions.
Q4 Seasonality and New Business Volatility
Q4 P&C new business CSM was modest due to seasonality and early recognition of a large proportional retrocession cover renewals; Life & Health results still show quarterly volatility despite full-year strength.
Refinancing and Capital Timing Risks
Financial leverage increased after a Tier 2 issuance and SCOR highlighted a potential repayment of EUR 283 million (remaining part of a EUR 600m Tier 2) with first call in June 2026, implying ongoing refinancing considerations.
Regulatory Reform Uncertainty
Solvency reform (implementation expected 2027) could have a negative impact; SCOR estimates a potential ~10–15 percentage point effect on solvency ratio (including loss of contingent capital benefit) pending final guidance.
Man-Made Loss Volatility
Q4 had a heavier level of man-made losses (Q3 also elevated), creating quarter-to-quarter volatility, although management states annual man-made losses remain within normal expectations.
Legal/Arbitration Uncertainty
An arbitration case remains pending with the panel decision expected mid-2026; existing provisions are stated as best estimates but the timing/outcome is uncertain.
Tax Rate and Structural Changes
Effective tax rate for FY2025 was ~28%; guidance assumption of ~30% for 2026 remains in place while the group completes tax/structure relocations (redomiciliation of an Irish platform to Paris) which have transitional effects.
Company Guidance
SCOR reiterated confidence in delivering its Forward ’26 targets, guiding to a P&C combined ratio below 87% in 2026 (nat‑cat budget ~10%; Q4 nat‑cat 7.6%, YTD 6.8%; Q4 attritional loss ratio 74.7%, YTD 76.4%), continued opportunistic buffer building (already above the initial €300m target), and net‑net operating capital generation of 3–5 percentage points of solvency ratio in 2026; key metrics cited include group solvency ratio 215% (up 5 pts vs 2024), economic value +13.7% at constant economics (EV/share €48), financial leverage 25.3% (from 24.5%), proposed dividend €1.90/share (+5.6% vs €1.80) setting a new floor, FY net income €846m and ROE 19.1% (Q4 net income €214m, Q4 annualized ROE 21.1%), Life & Health new business CSM FY €464m (Q4 €170m) and insurance service result FY €450m (Q4 €115m) vs ~€0.4bn target, P&C new business CSM +9% FY, investments RoIA 3.6% in Q4 with investment income €209m and regular yield 3.8%, management savings €170m achieved (costs flat vs 2023) and expense‑ratio guidance 7–8% (2025: 7.4%).

SCOR SE Financial Statement Overview

Summary
Overall fundamentals are solid but uneven. Cash flow is a strength (consistently positive operating cash flow and free cash flow), leverage appears reasonable for a reinsurer, and profitability has recovered versus the 2022 loss year. Offsetting this, revenue has drifted lower across recent years and profitability has been volatile, keeping the score in the mid-range.
Income Statement
58
Neutral
Revenue has been drifting lower over time (down in each of the last three annual periods, with a steep ~11.9% decline in 2025). Profitability is volatile: the company swung from a large loss in 2022 to strong profitability in 2023 and a healthy net margin in 2025 (~5.2%), but 2024 profitability was near break-even despite positive operating profit. Overall, earnings power looks recovered versus 2022, but the revenue contraction and year-to-year margin instability keep the score mid-range.
Balance Sheet
64
Positive
Leverage appears reasonable for a reinsurer, with debt generally below equity (debt-to-equity around ~0.69–0.78 in 2023–2024). Equity levels are fairly steady, and total debt is stable around ~$3.0–$3.6B, suggesting no aggressive balance-sheet expansion. A key watch-out is balance-sheet scale shifting over time (notably lower assets versus 2021), and some reported leverage/return fields look inconsistent in 2025, which reduces confidence in the trend read-through.
Cash Flow
71
Positive
Cash generation is a relative strength: operating cash flow has been consistently positive, and free cash flow is positive in every year provided. Free cash flow rebounded sharply in 2023 and remained solid in 2024–2025 (though 2025 fell ~11.9% and 2024 also declined). Cash flow has generally tracked reported earnings well in profitable years, supporting earnings quality, but the recent downshift in free cash flow growth tempers the score.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue17.67B15.57B15.65B15.84B16.44B15.99B
Gross Profit17.82B15.57B14.83B15.16B12.61B12.11B
EBITDA417.43M0.00520.00M1.58B-1.32B1.23B
Net Income541.00M817.41M4.00M812.00M-1.38B456.00M
Balance Sheet
Total Assets35.82B36.10B37.35B35.48B34.99B51.58B
Cash, Cash Equivalents and Short-Term Investments21.19B21.55B22.08B20.90B1.83B2.08B
Total Debt4.11B3.57B3.55B3.24B3.13B3.06B
Total Liabilities29.58B31.67B32.82B28.60B28.51B43.34B
Stockholders Equity4.13B4.43B4.52B4.69B4.32B6.41B
Cash Flow
Free Cash Flow1.10B973.02M875.00M1.45B430.00M2.32B
Operating Cash Flow1.16B1.01B903.00M1.48B500.00M2.41B
Investing Cash Flow-360.00M-848.15M-181.00M-954.00M-269.00M-1.54B
Financing Cash Flow-277.00M-347.71M-213.00M-428.00M-567.00M-674.00M

SCOR SE Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.30
Price Trends
50DMA
3.40
Positive
100DMA
3.30
Positive
200DMA
3.34
Positive
Market Momentum
MACD
0.03
Positive
RSI
51.32
Neutral
STOCH
36.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCRYY, the sentiment is Positive. The current price of 3.3 is below the 20-day moving average (MA) of 3.50, below the 50-day MA of 3.40, and below the 200-day MA of 3.34, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 51.32 is Neutral, neither overbought nor oversold. The STOCH value of 36.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCRYY.

SCOR SE Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$2.88B4.9122.09%22.79%-5.17%
80
Outperform
$12.75B4.7024.24%0.57%-3.96%-48.08%
73
Outperform
$13.18B11.389.48%1.76%2.10%19.23%
72
Outperform
$13.10B8.8310.61%2.37%8.62%-78.92%
71
Outperform
$2.45B5.5520.87%7.87%-4.68%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
67
Neutral
$6.25B62.9219.25%5.81%-0.73%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SCRYY
SCOR SE
3.49
0.49
16.44%
EG
Everest Group
324.30
-26.22
-7.48%
RGA
Reinsurance Group
201.03
6.27
3.22%
RNR
Renaissancere Holdings
293.23
55.00
23.09%
SPNT
SiriusPoint
20.95
4.70
28.92%
HG
Hamilton Insurance Group, Ltd. Class B
29.02
9.08
45.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 19, 2026